Advagene   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taipei Taiwan (2006)

Organization Overview

First Clinical Trial
2012
NCT03293732
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Advagene Biopharma Co. Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

ad17002 (4 trials)

Drugs in Phase 2 Trials (2)

ad07010 (1 trial)

inactivated influenza vaccine (1 trial)

Drugs in Phase 1 Trials (2)

dcb07010 (1 trial)

influenza ha antigen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5